Next-Generation Sequencing–Based Clonality Assessment of Ig Gene Rearrangements: A Multicenter Validation Study by EuroClonality-NGS

EuroClonality-NGS Working Group

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)

Abstract

Ig gene (IG) clonality analysis has an important role in the distinction of benign and malignant B-cell lymphoid proliferations and is mostly performed with the conventional EuroClonality/BIOMED-2 multiplex PCR protocol and GeneScan fragment size analysis. Recently, the EuroClonality-NGS Working Group developed a method for next-generation sequencing (NGS)–based IG clonality analysis. Herein, we report the results of an international multicenter biological validation of this novel method compared with the gold standard EuroClonality/BIOMED-2 protocol, based on 209 specimens of reactive and neoplastic lymphoproliferations. NGS-based IG clonality analysis showed a high interlaboratory concordance (99%) and high concordance with conventional clonality analysis (98%) for the molecular conclusion. Detailed analysis of the individual IG heavy chain and kappa light chain targets showed that NGS-based clonality analysis was more often able to detect a clonal rearrangement or yield an interpretable result. NGS-based and conventional clonality analysis detected a clone in 96% and 95% of B-cell neoplasms, respectively, and all but one of the reactive cases were scored polyclonal. We conclude that NGS-based IG clonality analysis performs comparable to conventional clonality analysis. We provide critical parameters for interpretation and discuss a first step toward a quantitative scoring approach for NGS clonality results. Considering the advantages of NGS-based clonality analysis, including its high sensitivity and possibilities for accurate clonal comparison, this supports implementation in diagnostic practice.

Original languageEnglish
Pages (from-to)1105-1115
Number of pages11
JournalJournal of Molecular Diagnostics
Volume23
Issue number9
DOIs
Publication statusPublished - 1 Sep 2021

Bibliographical note

Funding Information:
Supported by the Dutch Health Insurers' Innovation Fund project number 17-179; and the revenues of the previously obtained patent ( PCT/NL2003/000690 ), which is collectively owned by the EuroClonality/BIOMED-2 Consortium and licensed to Invivoscribe.

Publisher Copyright:
© 2021 Association for Molecular Pathology and American Society for Investigative Pathology

Fingerprint

Dive into the research topics of 'Next-Generation Sequencing–Based Clonality Assessment of Ig Gene Rearrangements: A Multicenter Validation Study by EuroClonality-NGS'. Together they form a unique fingerprint.

Cite this